Tag Archives: Tom Norton

Bringing New Rx Drugs to Market in 2014

by Tom Norton I did something today that I haven’t done in years: I checked out the US pharmaceutical R&D spend versus the rest of the world. Having known since the 80’s that the US owned this space, a quick look at the latest R&D figures confirmed my decades old understanding of the industry’s worldwide […]
Posted in Biotech, Corporate Responsibility, Emerging Markets, Europe, FDA, Global, Guest Blog, Market Access, pricing, Strategy | Also tagged , , , , , | 3 Comments

The Vanishing Rx Patient Assistance Programs?

by Tom Norton In the early 1990’s, during the debate over the Clinton healthcare plan, I recall sitting in an interesting meeting at my pharma company headquarters. In response to the Clinton’s charges that the industry was “price gouging,” my firm was proposing that we provide free prescription products to any patients who could not […]
Posted in Corporate Responsibility, Guest Blog, healthcare, Legal, Market Access, Patient Communication | Also tagged , , , , , , | 1 Comment

The First Day of Obamacare: Is US Pharma Ready?

by Tom Norton For more than three years, the US pharmaceutical industry has known that today would arrive. So this is it. The first day that eligible U.S. citizens can sign up for Obamacare — and enjoy the prospect of prescription drug insurance, effective January 1st, 2014. I have spent the last week surveying many […]
Posted in Guest Blog, healthcare, Legal, Market Access, pricing, R&D, Regulatory, Sales, Strategy | Also tagged , , , , , , , | 1 Comment

Rx Brand Managers: Will Your Products Be Covered Under Obamacare?

by Tom Norton We are now less than three weeks away from the initial sign up period for Obamacare. After October 1st, the reality of the program and all that it portends for the future of the US pharmaceutical industry will begin to make itself apparent. One area that is of extreme concern to Rx […]
Posted in Guest Blog, healthcare, Legal, Market Access, Regulatory, Strategy | Also tagged , , , , , , , | Leave a comment

No 'One Drug Per Therapeutic Class' for Congress

by Tom Norton As many of you may recall, earlier this year I commented on a section of the new Obamacare law that directed Members of Congress and their staffs to participate in the new healthcare program, effective January 1, 2014.  The theory was that if Congress mandated Obamacare for all Americans, then Members of […]
Posted in Guest Blog, healthcare, Legal, Regulatory, Strategy | Also tagged , , , , , , , , | Leave a comment
  • Categories

  • Meta